Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.
Zhang L, Chen L, Sah S, Latham GJ, Patel R, Song Q, Koeppen H, Tam R, Schleifman E, Mashhedi H, Chalasani S, Fu L, Sumiyoshi T, Raja R, Forrest W, Hampton GM, Lackner MR, Hegde P, Jia S. Zhang L, et al. Among authors: schleifman e. Oncologist. 2014 Apr;19(4):336-43. doi: 10.1634/theoncologist.2013-0180. Epub 2014 Mar 24. Oncologist. 2014. PMID: 24664487 Free PMC article.
Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.
Wilson TR, Xiao Y, Spoerke JM, Fridlyand J, Koeppen H, Fuentes E, Huw LY, Abbas I, Gower A, Schleifman EB, Desai R, Fu L, Sumiyoshi T, O'Shaughnessy JA, Hampton GM, Lackner MR. Wilson TR, et al. Among authors: schleifman eb. Breast Cancer Res Treat. 2014 Nov;148(2):315-25. doi: 10.1007/s10549-014-3163-8. Epub 2014 Oct 22. Breast Cancer Res Treat. 2014. PMID: 25338319 Free PMC article.
Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers.
Kim D, Choi Y, Ireland J, Foreman O, Tam RN, Patel R, Schleifman EB, Motlhabi M, French D, Wong CV, Peters E, Molinero L, Raja R, Amler LC, Hampton GM, Lackner MR, Kabbarah O. Kim D, et al. Among authors: schleifman eb. PLoS One. 2016 Nov 15;11(11):e0165856. doi: 10.1371/journal.pone.0165856. eCollection 2016. PLoS One. 2016. PMID: 27846280 Free PMC article.
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.
Wilson TR, Yu J, Lu X, Spoerke JM, Xiao Y, O'Brien C, Savage HM, Huw LY, Zou W, Koeppen H, Forrest WF, Fridlyand J, Fu L, Tam R, Schleifman EB, Sumiyoshi T, Molinero L, Hampton GM, O'Shaughnessy JA, Lackner MR. Wilson TR, et al. Among authors: schleifman eb. NPJ Breast Cancer. 2016 Jul 13;2:16022. doi: 10.1038/npjbcancer.2016.22. eCollection 2016. NPJ Breast Cancer. 2016. PMID: 28721382 Free PMC article.
Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA.
Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, Fendler B, Young L, Zhao M, Coyne M, Breese V, Young G, Donahue A, Pavlick D, Tsiros A, Brennan T, Zhong S, Mughal T, Bailey M, He J, Roels S, Frampton GM, Spoerke JM, Gendreau S, Lackner M, Schleifman E, Peters E, Ross JS, Ali SM, Miller VA, Gregg JP, Stephens PJ, Welsh A, Otto GA, Lipson D. Clark TA, et al. Among authors: schleifman e. J Mol Diagn. 2018 Sep;20(5):686-702. doi: 10.1016/j.jmoldx.2018.05.004. Epub 2018 Jun 22. J Mol Diagn. 2018. PMID: 29936259 Free PMC article.
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, Lieber DS, Lipson D, Silterra J, Amler L, Riehl T, Cummings CA, Hegde PS, Sandler A, Ballinger M, Fabrizio D, Mok T, Shames DS. Gandara DR, et al. Among authors: schleifman e. Nat Med. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6. Nat Med. 2018. PMID: 30082870
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort.
Dziadziuszko R, Mok T, Peters S, Han JY, Alatorre-Alexander J, Leighl N, Sriuranpong V, Pérol M, de Castro Junior G, Nadal E, de Marinis F, Frontera OA, Tan DSW, Lee DH, Kim HR, Yan M, Riehl T, Schleifman E, Paul SM, Mocci S, Patel R, Assaf ZJ, Shames DS, Mathisen MS, Gadgeel SM. Dziadziuszko R, et al. Among authors: schleifman e. J Thorac Oncol. 2021 Dec;16(12):2040-2050. doi: 10.1016/j.jtho.2021.07.008. Epub 2021 Jul 24. J Thorac Oncol. 2021. PMID: 34311110 Free article. Clinical Trial.
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T. Peters S, et al. Among authors: schleifman e. Nat Med. 2022 Sep;28(9):1831-1839. doi: 10.1038/s41591-022-01933-w. Epub 2022 Aug 22. Nat Med. 2022. PMID: 35995953 Free PMC article. Clinical Trial.
23 results